Demand for weight-loss drugs surged throughout 2024, outpacing supply for most of the year. In December, Novo Holdings, an ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly (NYSE: LLY) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news ...

Analysts are bullish on the maker of weight-loss drugs Zepbound and Mounjaro, with 10 of the 11 analysts who follow the company and are tracked by Visible Alpha rating Eli Lilly stock as a "buy ...

Investors don’t like tariffs. The S&P 500 was down 1.9% in morning trading Monday, and 91% of its component stocks were down, after President Donald Trump announced 25% tariffs on imports from ...

The flow of seaborne oil fell sharply in January, led by a plunge in shipments from Mexico and Brazil. The two nations’ slumps are a reminder of how volatile supply can be in a world where the ...

It marked the greatest single-day market-cap destruction for a company in U.S. stock market history. While the growth stock recovered nearly half of those losses the following day, there are still ...

The billionaire investor thinks this stock could skyrocket roughly 500% by early 2026. So why does Wall Street expect it to plunge? Although Fannie Mae wasn't a winner throughout much of the time ...

This would not only drive sales growth but also reinforce Eli Lilly's position as an innovator in the metabolic disease space, potentially leading to increased investor confidence and stock ...